【摘要】 目前,全球处于新型冠状病毒肺炎(COVID-19)大流行状态。糖尿病合并COVID-19患者病死率高。糖尿病与COVID-19可相互影响,新型冠状病毒(SARS-CoV-2)通过血管紧张素转化酶2(ACE2)受体感染胰岛细胞,细胞因子风暴、急性全身炎症反应损伤胰岛组织,减少胰岛素的分泌,引起血糖升高。同时,高血糖促进SARS-CoV-2感染细胞的过程;糖尿病患者免疫功能低下,加速COVID-19病情的进展。针对糖尿病合并COVID-19患者,二甲双胍、DPP-4抑制剂和他汀类药物具有改善炎症和免疫调节作用,可作为治疗的选择。DPP-4被发现是SARS-CoV-2的潜在结合靶点,为后续的研究提供了可能的方向。更多还原

【Abstract】 Nowadays,the world is in a pandemic of novel coronavirus pneumonia(COVID-19).Diabetes combined with COVID-19 has a high prevalence and fatality rate.Diabetes mellitus(DM) and COVID-19 interact with each other.SARS-CoV-2 infects islet cells through angiotensin-converting enzyme 2(ACE2) receptor to reduce insulin secretion.This virus can also cause cytokine storms and acute systemic inflammatory response,"which can damage islet tissues and cause the rise of blood glucose concentration.Meanwhile,hyperglycemia promotes cell infection of SARS-CoV-2.Diabetic patients with immune dysfunction accelerate the progression of COVID-19-Metformin,DPP-4 inhibitors and statins have multiple effects to improve inflammation and immunoregulatory function,and should be treatment options for diabetic patients with COVID-19.DPP-4 has been found to be a potential binding target of SARS-CoV-2,which provides a possible direction for future research.更多还原